BJH - volume 8, issue 4, august 2017
T. Feys MBA, MSc
(BELG J HEMATOL 2017;8(4):166–7)
Read moreBJH - volume 8, issue 4, august 2017
I. Moors MD
With the unraveling of the molecular basis of AML last year, new treatment options have arisen and new insights were established concerning disease response to therapy, its impact on prognosis and its relevance for post-remission treatment decisions.
(BELG J HEMATOL 2017;8(4):171–5)
Read moreBJH - volume 8, issue 3, june 2017
T. Lodewyck MD
The 43rd annual meeting of the European Society for Blood and Marrow Transplantation took place in Marseille between March 26th and March 29th, 2017. The society celebrated 60 years of history in the field of hematopoietic stem cell transplantation. This report summarises some interesting abstracts that were presented during the meeting.
(BELG J HEMATOL 2017;8(3):122–4)
Read moreBJH - volume 8, issue 2, march 2017
T. Feys MBA, MSc
(BELG J HEMATOL 2017;8(2):87–8)
Read moreBJH - volume 8, issue 1, february 2017
P. Vlummens MD
Multiple myeloma (MM) remains a devastating disease, even in the era of novel agents. As such, the search for new treatment modalities, alongside optimization of those already available, boldly continues. Each year, the ASH congress offers us the opportunity to learn about the latest developments in the MM field. This text aims to provide a brief summary of some of the latest insights presented at ASH this year.
(BELG J HEMATOL 2017;8(1):3–7)
Read moreBJH - volume 8, issue 1, february 2017
M. Maerevoet MD
ASH 2016 again featured a plethora of abstracts dedicated to lymphoma. In this summary we will discuss the studies that, in our opinion, have the highest relevance for daily clinical practice. This summary will not address indolent lymphoma as this will be covered in another article in this ASH special.
(BELG J HEMATOL 2017;8(1):10–3)
Read moreBJH - volume 8, issue 1, february 2017
T. Devos MD, PhD
The presentations on myeloproliferative neoplasms at this year’s ASH congress were inspiring and innovative. As expected, the main topic in chronic myeloid leukemia (CML) was treatment-free remission (TFR). About 30 oral or poster abstracts on this topic were presented during ASH 2016. An update of the important EURO-SKI trial and new results were presented: TFR-studies after treatment with 1st and 2nd generation tyrosine kinase inhibitors (TKI), as well as TFR-studies after both first and second attempts of TKI-discontinuation. While stopping TKI-treatment is considered in CML, starting new treatments and when to start was the main topic regarding the BCR-ABL negative MPNs polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF). A wide panoply of MPN-related topics has been presented at San Diego: late-breaking results of the second-generation JAK-inhibitor pacritinib in MF, interferon-trials in PV and ET, long-term treatment data of the JAK-TKI momelotinib and ruxolitinib, new molecules and novel molecular data, and finally, a special focus on quality of life (QOL). QOL has been a major topic in CML/MPN since several years. In this paper, some key abstracts on CML and MPN, presented at ASH 2016, are selected and commented. I’m aware that this selection excludes many other abstracts, not reducing their intrinsic value. The aim is to present a broad and representative spectrum of studies on each topic. At the end of the article, some ‘take-home messages’ will be given.
(BELG J HEMATOL 2017;8(1):16–22)
Read more
Top
